Mobocertinib succinate - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for mobocertinib succinate and what is the scope of patent protection?

Mobocertinib succinate is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mobocertinib succinate has sixty-two patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for mobocertinib succinate

International Patents:	62
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
DailyMed Link:	mobocertinib succinate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for mobocertinib succinate

Generic Entry Date for mobocertinib succinate^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for mobocertinib succinate

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inducers HER1 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for mobocertinib succinate

L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for mobocertinib succinate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for mobocertinib succinate

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Colombia	2017000386	Compuestos de heteroarilo para la inhibición de cinasa	⤷ Sign Up
Philippines	12016502453	HETEROARYL COMPOUNDS FOR KINASE INHIBITION	⤷ Sign Up
Costa Rica	20170011	COMPUESTOS DE HETEROARILO PARA LA INHIBICIÓN DE CINASA	⤷ Sign Up
New Zealand	726723	Heteroaryl compounds for kinase inhibition	⤷ Sign Up
Poland	3157916		⤷ Sign Up
Peru	20170268	COMPUESTOS DE HETEROARILO PARA LA INHIBICION DE CINASA	⤷ Sign Up
Brazil	112016029662	compostos de heteroaril para inibição de quinase	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for mobocertinib succinate

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3157916	C03157916/01	Switzerland	⤷ Sign Up	PRODUCT NAME: MOBOCERTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68147 01.06.2022
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for mobocertinib succinate

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for mobocertinib succinate

Pharmacology for mobocertinib succinate

Anatomical Therapeutic Chemical (ATC) Classes for mobocertinib succinate

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for mobocertinib succinate